biontech
BioNTech had a strong quarter despite slowing COVID sales.A robust pipeline makes it a takeover target for larger pharma companies.A share repurchase program should help support price action in 2023.5 stocks we like better than BioNTechBioNTech (NASDAQ:BNTX) got a substantial boost from the pandemic and its mRNA vaccine, developed with Pfizer (NYSE:PFE). The stock has seen a substantial correction since then due to slowing COVID sales, but the bottom is in. Q4 2022 hedge fund letters, conferences and more Find A Qualified Financial AdvisorEach advisor has been vetted by SmartAsset and is held ...
ValueWalk
The Food and Drug Administration approved COVID-19 vaccine booster shots for people with weakened immune systems, according to CNBC. With this move, the organization intends to protect the most vulnerable population from the delta variant, now prevalent in the country. Q2 2021 hedge fund letters, conferences and more Covid Booster AuthorizedActing FDA Commissioner Dr. Janet Woodcock said in a statement: “Today’s action allows doctors to boost immunity in certain immunocompromised individuals who need extra protection from COVID-19.” The measure will mean that organ transplant recipients, and H...
ValueWalk
An increasing number of studies shows that the new South African strain of COVID can infect people who have already had the disease, and that vaccines have little effect on it. It is possible that the entire current vaccination program could be rendered ineffective by this strain, that the vaccines will have to be improved, and the vaccination will have to be restarted from scratch. However, is the panic really justified? Q4 2020 hedge fund letters, conferences and more If we disregard the immediate emotional reaction and consider the statistics that we currently have, we can realise that the ...
ValueWalk
CNBC Exclusive: CNBC Transcript: BioNTech CEO Dr. Ugur Sahin speaks with CNBC’s “Squawk Box” today about Pfizer-BioNTech coronavirus vaccine being effective against new mutation strains in UK and South Africa. Q3 2020 hedge fund letters, conferences and more BioNTech CEO: Pfizer-BioNTech coronavirus vaccine effective against mutation strains in UK, South AfricaMEG TIRRELL: Andrew, thank you so much and Ugur Sahin, the BioNTech CEO, joins us now. Dr. Sahin, thank you for being with us to kick off our JPMorgan healthcare coverage. I want to start by asking you about your vaccine with Pfizer for ...
ValueWalk
Commenting on Pfizer and Biontech Covid vaccine candidate being approved in the U.K. and today’s trading Gorilla Trades strategist Ken Berman said: Q3 2020 hedge fund letters, conferences and more Following a very active morning session stock traded sideways throughout the afternoon, with only a few sectors registering heavy activity. Today’s session was another confirmation of the bullish regime shift in volatility, as, despite the overnight selloff in global risk assets, the Volatility Index (VIX) finished unchanged, and that could be foreshadowing a much calmer period for investors.” Pfizer...
ValueWalk
Commenting on Pfizer and Biontech filing for the emergency approval of their coronavirus vaccine candidate in Europe and today’s trading, Gorilla Trades strategist Ken Berman said:Q3 2020 hedge fund letters, conferences and morePfizer And Biontech File For Emergency ApprovalThe major indices are all trading significantly higher at midday, erasing yesterday’s losses and closing in on their record highs. The Nasdaq and the S&P 500 already hit new all-time highs in early trading, and the Dow also recaptured the historic 30,000 level. Risk assets surged higher overnight, lifting U.S. index futures...
ValueWalk
Pfizer and BioNTech have applied for approval for their COVID vaccine in Europe. The application is for conditional marketing authorization. BioNTech said if the European Medicines Agency (EMA) approves their application, Pfizer’s COVID vaccine could start being distributed in Europe this month.Pfizer, BioNTech seek approval for COVID vaccine in EuropeThe EMA said on its website that authorization is needed for medicines “that address unmet medical needs of patients on the basis of less comprehensive data than normally required.” The agency also said companies can apply for conditional marketi...
ValueWalk
Pfizer and BioNTech are planning to ask the Food and Drug Administration for emergency authorization for their COVID-19 vaccine today. It will be the first coronavirus vaccine to try to get regulatory approval in the U.S.Q3 2020 hedge fund letters, conferences and morePfizer, BioNTech to seek emergency authorization for vaccineThe two companies issued a statement saying that their COVID-19 vaccine candidate, which has officially been tagged as BNT162b2, could be available to high-risk populations in the U.S. by mid- to late December. The vaccine requires two injections given a few weeks apart....
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら